CalciMedica Inc., a clinical-stage biopharmaceutical company based in La Jolla, California, has released its financial results for the year ended December 31, 2025, alongside significant updates on its clinical programs. The company, which specializes in developing therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic conditions, highlighted key advancements in its ongoing trials.
In the Phase 2 KOURAGE trial focused on acute kidney injury (AKI), an internal and external review of safety data showed no evidence of drug-related toxicity associated with its lead candidate, AuxoraTM. Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, stated, “We look forward to discussions with the FDA about potential future clinical studies in AKI.” The company is also progressing towards a pivotal program in acute pancreatitis (AP), with plans to finalize the study design in the first half of 2026.
Clinical Updates and Trial Progress
The recent review of the KOURAGE trial, which evaluates Auxora in patients with Stage 2 or 3 AKI, led to the discontinuation of the study in January 2026. This decision followed a recommendation from the Independent Data Monitoring Committee (IDMC) regarding a mortality imbalance that necessitated a reevaluation of the study design. Importantly, the IDMC found no evidence of drug-related toxicity. The company aims to discuss the KOURAGE trial findings and potential future developments with the FDA in the second quarter of 2026.
Regarding the acute pancreatitis program, CalciMedica reported positive engagement with the U.S. Food and Drug Administration (FDA). The discussions are centered around the pivotal program for Auxora in AP, which, if successful, would be the first U.S. pivotal program assessing a therapeutic candidate for this condition, which sees approximately 300,000 hospitalizations annually in the U.S.
The results of the Phase 2b CARPO trial, published in eClinicalMedicine, demonstrated that Auxora significantly improved outcomes for patients with acute pancreatitis and systemic inflammatory response syndrome. Notably, the trial showed a statistically significant reduction in new-onset severe respiratory failure in the medium- and high-dose Auxora arms compared to placebo. In addition, the high-dose group achieved a win ratio of 1.640 across several critical endpoints, underscoring the drug’s potential in managing severe cases.
Financial Performance and Future Outlook
CalciMedica’s financial results reflect a robust operational plan moving forward. As of December 31, 2025, the company reported cash and cash equivalents of $13.0 million, which is expected to support operations through the fourth quarter of 2026. Research and development expenses rose slightly to $15.2 million, primarily due to increased clinical trial activities.
General and administrative expenses decreased to $7.9 million, reflecting a reduction in consultant and professional service costs. However, other expenses surged to $6.4 million, influenced by non-cash fair value adjustments and increased interest expenses, leading to a net loss of $29.6 million for the year. This translates to a loss of $1.97 per basic and diluted share, a significant increase from the previous year’s loss of $13.7 million.
CalciMedica is also advancing its second CRAC channel inhibitor, CM5480, for the treatment of pulmonary arterial hypertension (PAH). A recent publication in JCI Insight highlighted preclinical data suggesting that CM5480 may serve as a differentiated therapy in this area, with investigational new drug (IND) submission anticipated in 2027.
The ongoing efforts by CalciMedica reflect a commitment to addressing significant unmet needs in the treatment of acute and chronic inflammatory diseases. As the company prepares for pivotal discussions with regulatory agencies and continues to progress in its clinical trials, it remains focused on delivering innovative therapies to improve patient outcomes. For more information, visit CalciMedica’s website at www.calcimedica.com.
